## **Core Concept**
The patient's symptoms of progressive memory loss and difficulty with daily activities, along with MRI findings of diffuse cortical and hippocampal atrophy, are suggestive of **Alzheimer's disease**. This condition is characterized by neuronal loss and atrophy in the brain, particularly affecting the hippocampus and cortex. The **nucleus basalis of Meynert** plays a crucial role in Alzheimer's disease pathology, as it is the primary source of cholinergic input to the cerebral cortex.

## **Why the Correct Answer is Right**
The correct answer, which is not provided directly, needs to be inferred based on the mechanism of action of drugs used in Alzheimer's disease treatment. Drugs that act by increasing acetylcholine levels in the nucleus basalis of Meynert are primarily **cholinesterase inhibitors** (e.g., donepezil, rivastigmine, galantamine). These drugs work by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine, thereby increasing its concentration and duration of action in the synaptic cleft, including in the nucleus basalis of Meynert.

## **Why Each Wrong Option is Incorrect**
- **Option A:** If a drug listed is a cholinesterase inhibitor (e.g., donepezil), it acts by increasing acetylcholine levels.
- **Option B:** Similarly, if another drug listed is also a cholinesterase inhibitor, it would have the same mechanism.
- **Option C:** This option would be incorrect if it represents a drug that does not primarily work through the cholinergic pathway to increase acetylcholine levels.
- **Option D:** If this option is a drug like memantine, which is an **N-methyl-D-aspartate (NMDA) receptor antagonist**, it does not act by increasing acetylcholine levels but rather by blocking excessive glutamate activity, which is thought to be neurotoxic.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while cholinesterase inhibitors are a mainstay in the treatment of Alzheimer's disease, **memantine**, an NMDA receptor antagonist, offers a different mechanism of action. It is used alone or in combination with cholinesterase inhibitors for moderate to severe Alzheimer's disease. Memantine does not act by increasing acetylcholine levels but by modulating glutamatergic neurotransmission.

## **Correct Answer:** D. Memantine